Firstly, the results obtained for the complete group of ALK/EGFR-negative tumors stayed correct for the subgroup of treatment-naïve tumors: Tregs were higher in ALK-positive cancer compared to treatment-naïve ALK/EGFR-negative cancer (FC = 2.3, p = 0.00015). The gene discussed is ALK; the disease is cancer.